Select a medication above to begin.
Tepezza (teprotumumab-trbw)
teprotumumab
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = teprotumumab-trbw
thyroid eye dz
- [10 mg/kg/dose IV x1, then 20 mg/kg/dose IV q3wk x7 doses]
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- pregnancy
- caution: pts of childbearing potential
- caution: hyperglycemia
- caution: diabetes mellitus
- caution: inflammatory bowel dz
Drug Interactions .
Overview
teprotumumab
IGF-1R antagonist
- hyperglycemic effects
- ototoxicity
Avoid/Use Alternative
- amikacin
- amikacin inhaled
- ethacrynic acid
- gentamicin
- neomycin
- plazomicin
- streptomycin
- tobramycin
- tobramycin inhaled
Monitor/Modify Tx
- acarbose
- alogliptin
- amphotericin
- avanafil
- bexagliflozin
- bromocriptine
- bumetanide
- canagliflozin
- carboplatin
- chloroquine
- cisplatin
- colesevelam
- dapagliflozin
- deferasirox
- deferoxamine
- docetaxel
- dulaglutide
- eflornithine
- empagliflozin
- ertugliflozin
- exenatide
- fenoprofen
- fludarabine
- furosemide
- galsulfase
- glimepiride
- glipizide
- glyburide
- insulin
- isotretinoin
- itraconazole
- linagliptin
- liraglutide
- lixisenatide
- metformin
- miglitol
- naproxen
- nateglinide
- neomycin otic
- oxaliplatin
- paromomycin
- pioglitazone
- pramlintide
- quinidine (antiarrhythmic)
- quinidine (CYP2D6 inhibitor)
- quinine
- repaglinide
- rosiglitazone
- salsalate
- saxagliptin
- semaglutide
- sildenafil
- sitagliptin
- tadalafil
- tirzepatide
- torsemide
- vancomycin
- vardenafil
- vinblastine
- vincristine
- vinorelbine
Adverse Reactions .
Serious Reactions
- inflammatory bowel dz exacerbation
- ototoxicity, auditory
- hyperglycemia
- diabetic ketoacidosis
- hyperosmolar hyperglycemic state
Common Reactions
- muscle spasm
- nausea
- alopecia
- diarrhea
- fatigue
- hyperglycemia
- ototoxicity, auditory
- dry skin
- dysgeusia
- headache
- weight decr.
- nail disorder
- menstrual disorder
- infusion rxn
Safety/Monitoring .
Monitoring Parameters
glucose before each infusion and periodically during tx; audiometry at baseline, during tx, and after D/C
Pregnancy/Lactation .
Pregnancy
Clinical Summary
avoid use during pregnancy; no human data available; risk of fetal harm, incl. decr. fetal wt and skeletal abnormalities, based on animal data at 2.8x MRHD and drug's mechanism of action
Individuals of Reproductive Potential
avoid pregnancy by using effective contraception before tx start, during tx and x6mo after D/C in pts of childbearing potential
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: unknown; CYP450: unknown
Excretion: unknown; Half-life: 20 days
Subclass: IGF-1R Antagonists ; Thyroid Disorders: Thyroid Eye Disease
Mechanism of Action
exact mechanism of action unknown; antagonizes insulin-like growth factor-1 receptor (IGF-1R), preventing orbital fibroblast stimulation
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.